C4 Therapeutics

C4 Therapeutics announced positive Phase 1 results for cemsidomide in relapsed/refractory multiple myeloma. The drug demonstrated a 50% overall response rate at the highest dose, a favorable safety profile with no treatment discontinuations, and promising immunomodulatory effects. The company plans to initiate Phase 2 trials in Q1 2026 for fourth-line therapy and Phase 1b trials in Q2 2026 for second-line therapy in combination with BCMA BiTE, pursuing two potential accelerated approval pathways. The trial included 72 heavily pre-treated patients.